Invion (ASX:IVX) said the first patient was administered a dose of its topical formulation of its drug candidate, INV043, formulation of its lead drug candidate, INV043 in an open label Phase I/II trial for non melanoma skin cancer (NMSC), according to a Friday filing with the Australian bourse.
The open-label trial evaluates the safety and efficacy of INV043 for photodynamic cancer therapy, the filing said.
A safety review committee will assess whether to adjust the dose-light interval or expand the trial, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.